Publications

Constitutive Single Nucleotide Polymorphisms (Snp) Assessment for Predicting Tolerability and Efficacy of Triplet Hepatic Artery Infusion (Hai) and Intravenous Cetuximab (Iv-Cet) in Patients (Pts) with Liver Metastases from Colorectal Cancer (Lm-Crc) (European Trial Optiliv, Nct00852228).

AuthID
P-00P-9YY

Author(s)

Levi, F

Karaboue, A

Saffroy, R

Peyric, E

Ducreux, M

Smith, DM

Hebbar, M

Innominato, PF

Pernot, S

Carvalho, C

Guimbaud, R

Focan, CNJ

Bouchahda, M

Adam, R

Etienne Grimaldi, MC

Milano, GA

Lemoine, A

Group Author(s)

ARTBC Int

Document Type

Abstract

Year published

2014

Published

in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X

Volume: 32, Issue: 15

Conference

50Th Annual Meeting of the American-Society-Of-Clinical-Oncology, Date: MAY 30-JUN 03, 2014, Location: Chicago, IL, Sponsors: Amer Soc Clin Oncol

Indexing

Wos^®

Metadata
Sources

Publication Identifiers

Wos: WOS:000358613203109

Source Identifiers

ISSN: 0732-183X

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Constitutive Single Nucleotide Polymorphisms (Snp) Assessment for Predicting Tolerability and Efficacy of Triplet Hepatic Artery Infusion (Hai) and Intravenous Cetuximab (Iv-Cet) in Patients (Pts) with Liver Metastases from Colorectal Cancer (Lm-Crc) (European Trial Optiliv, Nct00852228).

Useful Links

Get Help

Federated Authentication (Click on the image)

Constitutive Single Nucleotide Polymorphisms (Snp) Assessment for Predicting Tolerability and Efficacy of Triplet Hepatic Artery Infusion (Hai) and Intravenous Cetuximab (Iv-Cet) in Patients (Pts) with Liver Metastases from Colorectal Cancer (Lm-Crc) (European Trial Optiliv, Nct00852228).

Useful Links

Get Help